(Q35011889)

5 August 2017

1 reference

title

Pharmacological treatments for prostate cancer (English)

1 reference

5 August 2017

2

Michael A Carducci

1 reference

5 August 2017

Janet R Walczak

1

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Expert Opinion on Investigational Drugs

5 August 2017

published in

1 reference

5 August 2017

volume

11

1 reference

5 August 2017

issue

12

1 reference

5 August 2017

page(s)

1737-1748

1 reference

5 August 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Phase II study of vinorelbine in patients with androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1737

10.1517/13543784.11.12.1737

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference